ABL1 and acute lymphoblastic leukemia: We observed that two separately derived BCR1-ABL+ hCD19+ B-ALL clones (“Methods”) demonstrated distinct responses to CAR T-cell treatment: partial response (m.PR) and complete response (m.CR).